T-Therapeutics is a biotechnology company focused on developing T cell receptor (TCR) therapeutics for cancer indications and inflammatory disorders. The company was founded in 2022 and is headquartered in Cambridge, UK.

T-Therapeutics

T-Therapeutics is a next-generation TCR company, spun out from the University of Cambridge, deeply rooted in world-leading academic science.  We are developing ‘optimal’ TCR based therapeutics using our proprietary OpTiMus® platform, based on a fully humanized TCR mouse that provides an almost unlimited source of unique, antigen-specific human TCRs.

We combine world-leading expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. 


T-Therapeutics Ltd

Great to have our £48m Series A fundraise covered by the @FinancialTimes this week. 
“We are at the dawn of a new age of therapeutics. TCR technology can target any cell in your body that you want to get rid of or control,” commented our CEO @Allan Bradley.
 
For the full article click here: https://lnkd.in/ejnJtmhS
 
#Cancer #TCR #TCELLS #Fundraise #TTherapeutics 

T-Therapeutics, spun out from @University of Cambridge, is revolutionising the treatment of cancer. 
 
 The Series A fundraise announced yesterday will support the development of therapeutics using our OpTiMus® platform, which enables the creation of an almost unlimited repertoire of ‘optimal’ TCRs as building blocks for pioneering therapies.

These therapies will harness the natural power of T cells, recruiting a patient’s own T cells to eradicate tumours. 

To find out more, please visit our website: https://t-therapeutics.com

#TCR #Cancer #Biotech #Tcell #researchanddevelopment 

  📣 We are excited to formally launch T-Therapeutics with the announcement of a £48 million Series A fundraise.  📣
 
The fundraise, led by Sofinnova Partners and F-Prime Capital along with participation from Digitalis Ventures, @Sanofi Ventures (www.sanofiventures.com) Cambridge Innovation Capital and Cambridge Enterprise will be used to further develop our pioneering OpTiMus platform to harness the natural power of T cells to build a portfolio of first-in-class cancer medicines.
 
Also delighted that Graziano Seghezzi, Nihal Sinha, Samuel Bjork and Robert Tansley have joined our Board of Directors.
 
To find out more, please visit our website: www.t-therapeutics.com
 
#R&D #Cancer #Biotech #Tcell #Immunooncology

Allan is looking forward to speaking at the Innovate Cambridge summit on Wednesday 11 October. Innovate Cambridge is creating an inclusive and ambitious innovation vision for the globally-leading future of the city’s already flourishing ecosystem. He will be speaking on ‘Maximising our unique strengths - How do we nurture the people that deliver pioneering discoveries? What Cambridge can do to accelerate the UK's lead globally?’. You can find out more about the summit and Innovate Cambridge at www.innovatecambridge.com #InnovateCambridge

COM:T-THERAPEUTICS

T-Therapeutics

People Not Available